VENMAX
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Venmax Drugs To Consider Merger With Hatri Pharma
Aug 25 (Reuters) - Venmax Drugs and Pharmaceuticals Ltd VENM.BO:
VENMAX DRUGS AND PHARMACEUTICALS LTD - VENMAX TO CONSIDER MERGER WITH HATRI PHARMA
Source text: ID:nBSE6b1m09
Further company coverage: VENM.BO
(([email protected];))
Aug 25 (Reuters) - Venmax Drugs and Pharmaceuticals Ltd VENM.BO:
VENMAX DRUGS AND PHARMACEUTICALS LTD - VENMAX TO CONSIDER MERGER WITH HATRI PHARMA
Source text: ID:nBSE6b1m09
Further company coverage: VENM.BO
(([email protected];))
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Venmax Drugs&Pharma do?
Venmax Drugs and Pharmaceuticals Limited engages in the manufacture and sale of bulk drugs intermediates primarily in India. It primarily offers trityl chloride. The company, formerly known as Yenkey Drugs and Pharmaceuticals Limited, was incorporated in 1988 and is based in Hyderabad, India.
Who are the competitors of Venmax Drugs&Pharma?
Venmax Drugs&Pharma major competitors are Starsource Multitrad, Zenith Health Care, Ishita Drugs & Inds., Cian Healthcare, Hamps Bio, Phaarmasia, Saroja Pharma Ind. Market Cap of Venmax Drugs&Pharma is ₹20 Crs. While the median market cap of its peers are ₹21 Crs.
Is Venmax Drugs&Pharma financially stable compared to its competitors?
Venmax Drugs&Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Venmax Drugs&Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Venmax Drugs&Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Venmax Drugs&Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances
How strong is Venmax Drugs&Pharma balance sheet?
Balance sheet of Venmax Drugs&Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Venmax Drugs&Pharma improving?
No, profit is decreasing. The profit of Venmax Drugs&Pharma is -₹0.01 Crs for Mar 2025, ₹0.06 Crs for Mar 2024 and ₹0.23 Crs for Mar 2023
Is the debt of Venmax Drugs&Pharma increasing or decreasing?
Yes, The net debt of Venmax Drugs&Pharma is increasing. Latest net debt of Venmax Drugs&Pharma is -₹2.47 Crs as of Jun-25. This is greater than Mar-25 when it was -₹4.92 Crs.
Is Venmax Drugs&Pharma stock expensive?
There is insufficient historical data to gauge this. Latest PE of Venmax Drugs&Pharma is 0
Has the share price of Venmax Drugs&Pharma grown faster than its competition?
Venmax Drugs&Pharma has given better returns compared to its competitors. Venmax Drugs&Pharma has grown at ~158.82% over the last 2yrs while peers have grown at a median rate of 1.0%
Is the promoter bullish about Venmax Drugs&Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Venmax Drugs&Pharma is 23.13% and last quarter promoter holding is 23.13%.
Are mutual funds buying/selling Venmax Drugs&Pharma?
There is Insufficient data to gauge this.
